Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer.
about
Tamoxifen: catalyst for the change to targeted therapyFourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancerA new day dawns: women without oestrogen or is a balance best?Estrogen as therapy for breast cancer.Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast CancerOptimal management of hormone receptor positive metastatic breast cancer in 2016The sequential use of endocrine treatment for advanced breast cancer: where are we?Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancersAlterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancerTamoxifen as the first targeted long-term adjuvant therapy for breast cancerRandomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis.Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer.Current and future directions in medical therapy for breast carcinoma: endocrine treatment.The Role of Hormonal Therapy in Breast Cancer.Endocrine Treatment - 'Old-Fashioned' Therapy Becoming Redundant in an Era of Molecular Medicine?Tamoxifen: a most unlikely pioneering medicine.Chains of evidence, mosaics of data: does estrogen 'cause' breast cancer? How would we know?A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality.Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer.Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents.Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis.Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.The BATTLE to personalize lung cancer prevention through reverse migration.The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.Diethylstilbestrol inhibits tumor growth and prolactin production in rat pituitary tumors.Changing concepts: Menopausal hormone therapy and breast cancer.The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistancePositron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized studyModels and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations.Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statementSelective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast CancerTemporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression.Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.Personalizing lung cancer prevention through a reverse migration strategy.Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?
P2860
Q24652988-FCAF198D-F080-41CB-956E-CE11D237A588Q24685693-ADD4AC5D-D578-4E3C-8B64-058914A16055Q24800226-89E5DC6F-3090-4D24-9FE8-BB1F1BD7675DQ24802521-E9A337AC-7B81-4962-938A-2E9CA0F82AB4Q26764987-F5335AC2-EE9F-48C2-8E20-C0B051790177Q26777683-E0906C22-FDC3-4BA4-AF60-6EF7B1FDAF1EQ26997396-F1F45246-67D3-4198-B4CC-0C10326CEF35Q28081872-365DE242-335A-4745-A3DF-63F561115E95Q28344327-27084007-F63E-4983-B07D-08D8764A7EB9Q33642104-4A4C78EB-16A9-4E7A-B74F-41A87145EBD6Q33698335-DEBF7AF2-2731-4E0D-A3EE-D67475524375Q33841512-99620DE5-5391-447A-8C09-696C70AF3370Q33847525-FEB137D2-93C1-438C-BAFD-BB5BC6FF2062Q33970582-4959177F-8DED-44E9-A9B5-4CAD4CBD5647Q34089338-3C331541-D55A-453A-9B57-3457350A4A7FQ34095945-322F6977-35E6-4FBD-8BCE-AE1204E57FCAQ34180688-A51FAC50-37C5-4FA0-A226-70EE48064275Q34285969-6B167082-6796-499D-BB60-E5592FCC92DBQ34324699-C2CFF738-2445-42C8-9F01-C4A890A182B3Q34362281-FBF9DB06-8B14-4A54-A005-ADE44D4FBF96Q34458253-22CBD6E4-354E-4CC2-9FAA-ADD4B3C0C898Q34736075-DBA4986F-24C3-4A9B-AE23-C2326037F189Q34944679-B6138053-261A-4E32-8B7D-00539CD60F3DQ35002418-412ECA00-AF08-4F6F-9FBD-1ABA3F8BC3D9Q35023715-39C8B8E6-04B6-4D14-9F50-CC27DAA937C0Q35208501-FB7A133F-0A07-4CB7-A094-62250315182CQ35827822-71A45172-12AC-480E-BFA3-7538A4891A05Q35835196-7C4F5F94-9068-4A5C-B8BD-BEF7B9ED71D3Q35866374-2CFD4241-6CAF-45F7-B294-798F04A0002FQ35939435-2873F9D0-3CD8-4381-AD6B-7D2DCA75134BQ36011096-6B3D4336-BA8F-4032-BA4E-56AFE622D93EQ36285977-72E6EE4B-C251-4D91-AE7D-06700B38CF97Q36517144-86E436EA-F687-43AE-BC47-C4ABD5A1AC5CQ36568571-CB26B13D-6455-4346-94E6-862506F0FA79Q36656704-B500B7C1-5261-4ED0-8CDB-85EAB5022142Q36892561-51CAD3E6-0756-40CD-B6D0-323C126065D8Q36993383-C2A21200-CDB6-40CD-ACC5-BA14CFC4E799Q37080513-B738E65F-8C75-4E04-8C8A-03FF712AFF14Q37182310-46E061D4-4377-4DB0-A45F-96BF9383291FQ37277121-3A6A972A-38C4-4D79-84DF-AEC61E7C46C7
P2860
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer.
description
1981 nî lūn-bûn
@nan
1981 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1981 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
name
Randomized clinical trial of d ...... n with advanced breast cancer.
@ast
Randomized clinical trial of d ...... n with advanced breast cancer.
@en
Randomized clinical trial of d ...... n with advanced breast cancer.
@nl
type
label
Randomized clinical trial of d ...... n with advanced breast cancer.
@ast
Randomized clinical trial of d ...... n with advanced breast cancer.
@en
Randomized clinical trial of d ...... n with advanced breast cancer.
@nl
prefLabel
Randomized clinical trial of d ...... n with advanced breast cancer.
@ast
Randomized clinical trial of d ...... n with advanced breast cancer.
@en
Randomized clinical trial of d ...... n with advanced breast cancer.
@nl
P2093
P1476
Randomized clinical trial of d ...... n with advanced breast cancer.
@en
P2093
Creagan ET
Edmonson JH
Nichols WC
P356
10.1056/NEJM198101013040104
P407
P577
1981-01-01T00:00:00Z